Alverine citrate promotes myogenic differentiation and ameliorates muscle atrophy

Cited 0 time in scopus
Metadata Downloads
Title
Alverine citrate promotes myogenic differentiation and ameliorates muscle atrophy
Author(s)
Jong Hyeon Yoon; Seung-Min Lee; Y Lee; Min Ju Kim; Jae Won Yang; Jeong Yi Choi; Ju Yeon KwakKwang-Pyo LeeYong Ryoul YangKi-Sun Kwon
Bibliographic Citation
Biochemical and Biophysical Research Communications, vol. 586, pp. 157-162
Publication Year
2022
Abstract
Sarcopenia is the age-related loss of muscle mass and function and no pharmacological medication has been approved for its treatment. We established an atrogin-1/MAFbx promoter assay to find drug candidates that inhibit myotube atrophy. Alverine citrate (AC) was identified using high-throughput screening of an existing drug library. AC is an established medicine for stomach and intestinal spasms. AC treatment increased myotube diameter and inhibited atrophy signals induced by either C26-conditioned medium or dexamethasone in cultured C2C12 myoblasts. AC also enhanced myoblast fusion through the upregulation of fusion-related genes during C2C12 myoblast differentiation. Oral administration of AC improves muscle mass and physical performance in aged mice, as well as hindlimb-disused mice. Taken together, our data suggest that AC may be a novel therapeutic candidate for improving muscle weakness, including sarcopenia.
Keyword
Alverine citrateSarcopeniaSkeletal muscle atrophyAging
ISSN
0006-291X
Publisher
Elsevier
DOI
http://dx.doi.org/10.1016/j.bbrc.2021.11.076
Type
Article
Appears in Collections:
Division of Research on National Challenges > Aging Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.